Imperagen lands £5M to speed up enzyme engineering with AI and quantum models

Imperagen has raised £5 million to push a big idea in biotech: using AI and quantum physics-based modeling to improve how enzymes are engineered.

The company is focused on one of the hardest parts of modern biological design. Enzymes power everything from drug development to manufacturing processes, but making them better suited for a specific task is often slow, messy and expensive. A lot of the work still depends on repeated testing, educated guesses and long iteration cycles.

Imperagen’s pitch is that this process can be made far more efficient. Instead of relying only on conventional screening and machine learning, the startup says it is building a platform that brings together AI with models grounded in quantum physics to better predict how enzymes behave.

That matters because enzyme performance comes down to chemistry at a very small scale. Tiny changes in structure can affect how an enzyme binds, reacts and holds up under different conditions. In theory, better physics-aware prediction could help researchers identify promising designs earlier and avoid wasting time on weak candidates.

The financing gives Imperagen fresh room to build out that vision. For early-stage biotech infrastructure companies, the challenge is not just proving the science, but showing that a new platform can fit into how researchers and commercial teams actually work. Speed, reproducibility and clear performance gains will matter more than buzzwords.

The timing also fits a broader trend. AI has already become a major force in drug discovery and protein design, but there is growing interest in pushing beyond pattern recognition alone. Companies and researchers are increasingly looking at ways to combine data-driven systems with deeper physical simulation, especially in areas where small molecular interactions determine real-world outcomes.

That is where Imperagen is trying to stand out. The company is not just selling AI as a shortcut. It is making a more ambitious claim: that better modeling of the underlying chemistry can improve enzyme design in a meaningful, commercially useful way.

If that works, the addressable market is broad. Enzymes are used throughout pharma, agriculture, food, specialty chemicals and industrial biotech. Better engineered enzymes can improve efficiency, reduce energy use, cut waste and unlock reactions that are difficult to achieve through traditional chemistry alone.

There is still plenty to prove. Using quantum methods in commercial biotech workflows is a compelling idea, but the real test will be whether the platform can deliver better outcomes at practical speed and cost. In this category, scientific elegance only goes so far unless it translates into measurable results.

Still, investors continue to back startups aiming to rebuild the tools behind biology. Imperagen’s new funding suggests there is appetite for platforms that promise not just more automation, but a smarter model of how biological chemistry actually works.

For a field defined by iteration, any credible way to make enzyme engineering faster and more predictable will get attention. Imperagen now has new capital to try to prove it can do exactly that.